Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 16/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CDK9 | P50750 | 3/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913605 | 0.87 | PDPK1 (0.49) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913606 | 0.87 | PDPK1 (0.49) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1915353 | 0.85 | PDPK1 (0.52) | PDPK1 | |
| SCHEMBL1915921 | 0.85 | PDPK1 (0.38) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL12530547 | 0.78 | PDPK1 (0.51) | PDPK1 | |
| SCHEMBL1913542 | 0.77 | PDPK1 (0.53) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913619 | 0.76 | PDPK1 (0.50) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913448 | 0.76 | PDPK1 (0.50) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913547 | 0.76 | PDPK1 (0.50) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1915229 | 0.76 | PDPK1 (0.57) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999986-B2 | Pyrrolo [2,3—D] pyrazin—7—ylpyrimidine compounds | MERCK PATENT GMBH (DE) | 2015-04-07 | — | — | US | claimed |
| EP-2516442-B1 | Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds | MERCK PATENT GMBH (DE) | 2013-12-25 | — | — | EP | claimed |
| EP-2516442-A1 | PYRROLO[2,3-D]PYRAZIN-7-YL PYRIMIDINE COMPOUNDS | Merck Patent GmbH (DE) | 2012-10-31 | — | — | EP | claimed |
| US-20120270880-A1 | PYRROLO [2,3-D] PYRAZIN-7-YLPYRIMIDINE COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | claimed |
| WO-2011076327-A1 | PYRROLO[2,3-D]PYRAZIN-7-YL PYRIMIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | claimed |
| US-8999986-B2 | Pyrrolo [2,3—D] pyrazin—7—ylpyrimidine compounds | MERCK PATENT GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999986-B2 | Pyrrolo [2,3—D] pyrazin—7—ylpyrimidine compounds | MERCK PATENT GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999986-B2 | Pyrrolo [2,3—D] pyrazin—7—ylpyrimidine compounds | MERCK PATENT GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2516442-B1 | Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds | MERCK PATENT GMBH (DE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2516442-A1 | PYRROLO[2,3-D]PYRAZIN-7-YL PYRIMIDINE COMPOUNDS | Merck Patent GmbH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20120270880-A1 | PYRROLO [2,3-D] PYRAZIN-7-YLPYRIMIDINE COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270880-A1 | PYRROLO [2,3-D] PYRAZIN-7-YLPYRIMIDINE COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270880-A1 | PYRROLO [2,3-D] PYRAZIN-7-YLPYRIMIDINE COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2011076327-A1 | PYRROLO[2,3-D]PYRAZIN-7-YL PYRIMIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270880-A1 | PYRROLO [2,3-D] PYRAZIN-7-YLPYRIMIDINE COMPOUNDS | MKI67, CDK4, CDK2 | PDPK1 111/4885CCNT1 182/4885CCNA2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.